Myocarditis as a manifestation of the disease COVID-19 and after vaccination against this disease
Authors:
Eliška Sovová
Authors place of work:
Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace LF UP a FN Olomouc
Published in the journal:
Čas. Lék. čes. 2022; 161: 135-138
Category:
Review Article
Summary
Although the involvement of the heart muscle in the coronavirus disease 2019 (COVID-19) is relatively common (5-10%), myocarditis is a complication with a much lower incidence, depending, however, on the diagnostic methods used. The pathophysiological mechanisms have been described, but there are significant gaps in current knowledge.
Myocarditis in connection with vaccination against the disease COVID-19 is a separate nosological unit. Even here, the pathophysiological processes are not explored in detail. The incidence of this complication is estimated in the low tens per million vaccinated.
Keywords:
vaccination – myocarditis – COVID-19
Zdroje
1. Bozkurt B, Das S. R, Addison D et al. 2022 AHA/ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol 2022; 80: 388–465.
2. Gluckman TJ, Bhave NM, Allen LA et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2022; 79: 1717–1756.
3. Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648.
4. Ferreira VM, Schulz-Menger J, Holmvang G et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018; 72: 3158-3176.
5. Law YM, Lal AK, Chen S et al. Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association. Circulation 2021; 144: e123–e135.
6. Ammirati E, Frigerio M, Adler ED et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document. Circ Heart Fail 2020; 13: e007405.
7. Tschöpe C, Ammirati E, Bozkurt B et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021; 18: 169–193.
8. Dai H, Lotan D, Much AA et al. Global, regional, and national burden of myocarditis and cardiomyopathy, 1990–2017. Front Cardiovasc Med 2021; 8: 610989.
9. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol 2021; 50: 107300.
10. Castiello T, Georgiopoulos G, Finocchiaro G et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev 2022; 27: 251–61.
11. Patone M, Mei XW, Handunnetthi L et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022; 28: 410–422.
12. Tuvali O, Tshori S, Derazne E et al. The incidence of myocarditis and pericarditis in post COVID-19 unvaccinated patients: a large population-based study. J Clin Med 2022; 11: 2219.
13. Ammirati E, Lupi L, Palazzini M et al. Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis. Circulation 2022; 145: 1123–1139.
14. Stáreková J, Bluemke DA, Bradham WS et al. Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol 2021; 6: 945–950.
15. Daniels CJ, Rajpal S, Greenshields JT et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol 2021; 6: 1078–1087.
16. Modica G, Bianco M, Sollazzo F et al. Myocarditis in athletes recovering from COVID-19: a systematic review and meta-analysis. Int J Environ Res Public Health 2022; 19: 4279.
17. Chevalier L, Cochet H, Mahida S et al. Resuming training in high-level athletes after mild COVID-19 infection: a multicenter prospective study (ASCCOVID-19). Sports Med Open 2022; 8: 83.
18. Casasco M, Iellamo F, Scorcu M et al. Return to play after SARS-CoV-2 infection in competitive athletes of distinct sport disciplines in Italy: a FMSI (Italian Federation of Sports Medicine) study. J Cardiovasc Dev Dis 2022; 9: 59.
19. Baigent C., Windecker S. et al.; Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1 – epidemiology, pathophysiology, and diagnosis. Eur Heart J 2022; 43: 1033–1058.
20. Kiblboeck D, Klingel K, Genger M et al. Myocarditis following mRNA COVID-19 vaccination: call for endomyocardial biopsy. ESC Heart Fail 2022; 9: 1996–2002.
21. Meier C, Korthals D, Bietenbeck M et al. Serial cardiovascular magnetic resonance studies prior to and after mRNA-based COVID-19 booster vaccination to assess booster-associated cardiac effects. Front Cardiovasc Med 2022; 9: 877183.
22. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144: 471–484.
23. Witberg G, Barda N, Hoss S et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med 2021; 385: 2132–2139.
24. Mevorach D, Anis E, Cedar N et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med 2021; 385: 2140–2149.
25. Karlstad Ø, Hovi P, Husby A et al. SARS-CoV-2 vaccination and myocarditis in a Nordic Cohort Study of 23 million residents. JAMA Cardiol 2022; 7: 600–612.
26. Oster ME, Shay DK, Su JR et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021. JAMA 2022; 327: 331–340.
27. Power JR, Keyt LK, Adler ED. Myocarditis following COVID-19 vaccination: Incidence, mechanisms, and clinical considerations. Expert Rev Cardiovasc Ther 2022; 20: 241–251.
28. Ling RR, Ramanathan K, Tan FL et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med 2022; 10: 679–688.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
2022 Číslo 3-4
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Bartter and Gitelman syndromes
- Současná bariatrická/metabolická chirurgie
- Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection – a ten-year single-center experience
- Use of unmanned aerial systems in the health care